CHARLES SCHWAB INVESTMENT MANAGEMENT INC

Position in NGNE — Neurogene Inc.

CIK 884546 SAN FRANCISCO, CA

Position in NGNE

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$1,029,735

+$423,766 QoQ

Shares Held

32,742

+8.9% QoQ

Ownership

0.164%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#40

of 111 holders

Holding Since

Mar 2024

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $7,346,663,053 across 299 Biotechnology names. NGNE ranks #224 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	2,041,282	$1,013,966,007
2	REGN	Regeneron Pharmaceuticals, Inc.	846,306	$527,705,642
3	RVMD	Revolution Medicines, Inc.	1,917,025	$359,020,441
4	MRNA	Moderna, Inc.	4,838,884	$338,867,045
5	ALNY	Alnylam Pharmaceuticals, Inc.	755,377	$227,391,137
6	INCY	Incyte Corp	1,692,439	$191,854,884
7	RPRX	Royalty Pharma plc	3,083,528	$172,893,414
8	CYTK	Cytokinetics Inc	1,565,781	$133,388,883

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,029,735	32,742	+8.9%	Shares	Sole	2026-08-14
2026-03-31	$605,969	30,058	+0.3%	Shares	Sole	2026-05-15
2025-12-31	$617,155	29,959	0.0%	Shares	Sole	2026-02-13
2025-09-30	$519,189	29,959	0.0%	Shares	Sole	2025-11-10
2025-06-30	$447,887	29,959	-11.8%	Shares	Sole	2025-08-12
2025-03-31	$397,776	33,969	+12.0%	Shares	Sole	2025-09-15
2024-12-31	$693,046	30,317	0.0%	Shares	Sole	2025-02-06
2024-09-30	$1,272,101	30,317	+2.5%	Shares	Sole	2024-11-12
2024-06-30	$1,076,270	29,576	+464.5%	Shares	Sole	2024-08-12
2024-03-31	$266,665	5,239	—	Shares	Sole	2024-05-09
No filing history on record for this holder in this stock.